Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XEN D0501

Next Previous
Drug Profile

XEN D0501

Alternative Names: BAY-69-9426; XEND0501

Latest Information Update: 30 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xention
  • Developer Ario Pharma; PILA PHARMA
  • Class Antihyperglycaemics; Small molecules; Urologics
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythromelalgia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Discontinued Cough; Overactive bladder

Most Recent Events

  • 01 Jul 2022 XEN D0501 receives Orphan Drug status for Erythromelalgia in USA (Pila Pharma pipeline, November 2023)
  • 10 Mar 2021 Phase II development is ongoing in Type-2 diabetes mellitus in Lithuania and Denmark (Pila Pharma pipeline, March 2021)
  • 10 Mar 2021 Pila Pharma plans a phase IIb trial in Type-2 diabetes mellitus (PO) (Pila Pharma pipeline, March 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top